drugset / Trial / NCT03990103
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs. S1 plus oxaliplatin intravenous injection as first-line treatment in gastric or gastroesophageal junctional adenocarcinoma with malignant ascites.
Timeline
- Start
- 2017-11-01
- Primary completion
- 2021-04-30
- Completion
- 2022-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 200 mg | Other |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 20 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 50 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 70 mg/m2 | Other |
| Background | S-1 | Small molecule | 80 mg | Oral |
| Background | S-1 | Small molecule | 120 mg | Oral |